• No results found

Title: State of the heart : the promise of pluripotent stem cell-derived cardiomyocytes in disease modelling, differentiation and development

N/A
N/A
Protected

Academic year: 2021

Share "Title: State of the heart : the promise of pluripotent stem cell-derived cardiomyocytes in disease modelling, differentiation and development "

Copied!
5
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Cover Page

The handle http://hdl.handle.net/1887/43820 holds various files of this Leiden University dissertation.

Author: Berg, C.W. van den

Title: State of the heart : the promise of pluripotent stem cell-derived cardiomyocytes in disease modelling, differentiation and development

Issue Date: 2016-10-26

(2)

C H A P T E R

English summary 8

(3)

R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 R15 R16 R17 R18 R19 R20 R21 R22 R23 R24 R25 R26 R27 R28 R29 R30 R31 R32 R33 R34 R35 R36 R37 R38 R39

8

Chapter 8

184

(4)

R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 R15 R16 R17 R18 R19 R20 R21 R22 R23 R24 R25 R26 R27 R28 R29 R30 R31 R32 R33 R34 R35 R36 R37 R38 R39

8

185 Pluripotent stem cells (PSCs) can multiply indefinitely in culture and differentiate into all specialized somatic cells of the adult body. We make use of embryonic stem cells (ESCs), isolated from the pre-implantation embryos, and induced pluripotent stem cells (iPSCs), generated by reprogramming somatic cells to understand human cardiac lineage development and disease.

Chapter 1 introduces the pluripotent stem cell field historically from the first derivation of ESCs and how to maintain these cells in a pluripotent state in vitro. The generation of iPSCs revolutionized the stem cell field in 2007 because it allowed pluripotent stem cells to be derived from individuals with diseases, so that if the disease had a genetic origin the cells could provide a model for it. Both types of pluripotent stem cells can differentiate into cells from all three germ layers of the developing foetus, including endothelial cells and cardiomyocytes of the cardiovascular system. The review describes cardiac differentiation protocols and how they mimic early cardiac development in the embryo. Aside from using these cells for modelling genetic diseases, we conclude that we can also use these cells for studying development as well as for drug and toxicity testing and possibly regenerative medicine.

Chapter 2 continues to evaluate the possible applications of PSC-derived cardiomyocytes in the context of studying cardiac diseases. These cells give the unique opportunity to generate human cardiomyocytes in vitro from both healthy individuals and from patients. We provide examples of several cardiac diseases, such as ion channelopathies and cardiomyopathies and the potential of PSCs in their study. In addition, we expound the use of PSCs in cardiac drug discovery and development, and the challenges for future research.

To investigate the possibility of studying inherited cardiac diseases using pluripotent stem cells, we compared how similar PSC-derived cardiomyocytes were to cardiomyocytes isolated from the heart itself. Chapter 3 describes research on a complex cardiac overlap syndrome caused by a mutation (1795insD) in SCN5A – a gene encoding a sodium ion channel that causes both a gain- and loss-of-function genetic disorder. Patients with the mutation can display symptoms of both long-QT syndrome type 3 and Brugada syndrome. First, we generated iPSCs from a mouse with the analogous SCN5A mutation. This mutation had also previously been introduced into mouse ESCs. We were able to show that cardiomyocytes from both the iPSCs and ESCs displayed similar altered electrophysiological properties as primary cardiomyocytes isolated from adult heterozygous mice with the same mutation. We then derived human iPSCs from a patient with the SCN5A-1795insD mutation. The cardiomyocytes derived from these human cells showed changes in the biophysical properties similar to those observed in all three types of mouse cardiomyocytes. We also demonstrated that both ESC- and iPSC-

(5)

R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 R15 R16 R17 R18 R19 R20 R21 R22 R23 R24 R25 R26 R27 R28 R29 R30 R31 R32 R33 R34 R35 R36 R37 R38 R39

8

Chapter 8

186

derived cardiomyocytes can recapitulate the characteristics of a complex overlap syndrome, despite of the electrophysiological immaturity of PSC-derived cardiomyocytes.

The research next focused on refining the techniques to differentiate the human PSCs to cardiomyocytes. Chapter 4 contains a detailed description of a directed cardiac differentiation protocol for pluripotent stem cells. We developed a monolayer differentiation procedure to generate cultures comprising of ~50 % cardiomyocytes. We use defined media that is effective for maintaining various pluripotent stem cell cultures in an undifferentiated state as a starting point. This was the only protocol that supported the growth and differentiation of several hESC and hiPSC lines under identical conditions. Furthermore we outlined protocols to quantify and evaluate the efficiency of differentiation.

These protocols were applied in the study comparing hESC- and hiPSC- derived cardiomyocytes directly at different time points during cardiac differentiation that is described in chapter 5.

The fluorescent marker GFP was targeted to one allele of NKX2-5 in a hiPSC line that now matched a similar hESC reporter line previously generated in the laboratory. This offered the opportunity to obtain cardiomyocytes and their precursors at different time points during the differentiation and determine the true degree of similarity between both PSC sources since both lines were maintained and differentiated under identical defined conditions. We found that comparable cardiac populations derived from both ESCs and iPSCs could be isolated.

Gene expression profiling comparing these cell lines during differentiation indicated that hiPSCs are very similar to hESCs and are a useful surrogate to study early cardiac development and serve as a replacement for cardiomyocytes derived from hESCs.

The same hESC- and hiPSC-derived cardiomyocytes were also compared to a unique set of fetal heart samples. Chapter 6 focuses on the gene expression profiles of matched atria and ventricles from several time points during the first and second trimester of development and these were compared to hESC- and hiPSC-derived cardiomyocytes. We found that PSC- derived cardiomyocytes most closely matched the first trimester heart samples, but when PSC-derived cardiomyocytes are cultured in a medium containing thyroid hormone they could mature and were more closely related to the second trimester samples.

Finally, in chapter 7 the results of the studies are summarized and discussed in the light of implications for future research.

Referenties

GERELATEERDE DOCUMENTEN

Subsequently, MIP-iECs were implanted into syngeneic recipients and grafts characterized for elements of innate and adaptive immune response such as the percentages of

For the first experiment, isolated T cells from C+I- vaccinated or vehicle (PBS+CpG)-vaccinated mice were adoptively transferred to a group of tumor bearing orthotopic breast

Here, we have undertaken direct side-by-side comparison of hiPSC-ECs with primary ECs, such as human dermal blood ECs (HDMECs) and HUVECs, in several widely used functional in vitro

Comparison of junctional integrity in primary and hiPSC- ECs (A-D) Junctional integrity in primary cells and hiPSC-ECs was analysed using tight junctional marker

Here we describe methods for determining real-time intracellular Ca 2+ release and contraction in vSMCs of neural crest origin differentiated from human induced pluripotent

Equine embryos at the compacted morula and blastocyst stage can be obtained by intracytoplasmic sperm injection (ICSI) of in vitro matured oocytes with frozen-thawed spermatozoa

The first reported generation of human induced pluripotent stem cells (iPS cells) and iPS cell- derived cardiomyocytes in the Netherlands.. Ward-van Oostwaard,

Third, as dialogical use of social media is widely argued to have positive outcomes for stakeholder relationships, this is tested, along with the effect of the combination